Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis

• Published in: Clinics and research in hepatology and gastroenterology Vol. 47; no. 10; p. 102227
• Main Authors: Jang, Hyejung, Han, Nayoung, Staatz, Christine E., Kwak, Jae-Hwan, Baek, In-hwan
• Format: Journal Article
• Language: English
• Published: Elsevier Masson SAS 01.12.2023
• Subjects: Meta-analysis; Metabolic dysfunction-associated steatohepatitis; Obeticholic acid; Primary biliary cholangitis; PICO; NAS; TIMP-1; ALP; ALT; SLD; UDCA; IL-23; HDL-C; PBC; ULN; SREBP1c; CINAHL; Metabolic dysfunction-associated steatohepatitis; ROB; SMD; FGF-19; IL-12; MASLD; IL-6; GIR; RCTs; BA; CRP; P3NP; RR; FXR; IgA; NAFLD; LDL-C; F; IgG; MASH; M; IgM; SD; WHO-ICTRP; TGF-β; BMI; AST; Obeticholic acid; CI; PRISMA; NASH; OCA; Meta-analysis; TC; TG; TNF-α; GGT; Primary biliary cholangitis; ELF

•OCA was associated with a significant increase in LDL-C and decrease in HDL-C in patients with PBC and MASH.•OCA was more efficacious than the placebo in treating PBC and MASH with respect to primary and secondary outcomes.•A significantly increased risk of pruritus was observed only in patients wh...